Antioxidant Effect of Thioredoxin and Vitamin D3 in Peritoneal Dialysis Patients

Table 3

Evaluation according PD type, etiology, and medical treatment.

		Thioredoxin
		PD type		CAPD ()	(58,5)	^b0,921
APD ()	(51,4)
Etiology	HT ()	(54,4)	^c0,488
	DM ()	(69,2)
	Polycystic kidney disease ()	(50,1)
	Others ()	(61,5)
	GMN ()	(282,8)
Drugs
Icodextran	Absent ()	(50,5)	^b0,364
	Present ()	(65,3)
Amino acid solutions	Absent ()	(53,4)	^b0,561
	Present ()	(68,7)
Erythropoietin	Not using ()	(50,9)	^b0,576
	Using ()	(62,2)
Oral	Not using ()	(52,5)	^b0,493
Antilipidemic	Using ()	(69,2)
Insulin treatment	Absent ()	(51,6)	^b0,280
	Present ()	(73,1)
Iron treatment	Absent ()	(53,4)	^b0,634
	Present ()	(62,4)
Amino acids	Absent ()	(53,4)	^b0,513
	Present ()	(65)
Phosphorus	Absent ()	(53,4)	^b0,694
Binding	Present ()	(54,2)
Vitamin D3	Absent ()	(42,5)	^b0,006
	Present ()	(68,3)

^bMann–Whitney test. ^cKruskal-Wallis test. . CAPD: Continuous ambulatory peritoneal dialysis; APD: Automated peritoneal dialysis; HT: Hypertension; DM: Diabetes mellitus, GMN: Glomerulonephritis.